Volume 6, Issue 4 pp. 352-355

Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen

Sander Florman

Sander Florman

The Recanati/Miller Transplantation Institute and

Search for more papers by this author
Corinne Benchimol

Corinne Benchimol

The Recanati/Miller Transplantation Institute and

Search for more papers by this author
Kenneth Lieberman

Kenneth Lieberman

The Recanati/Miller Transplantation Institute and

Search for more papers by this author
Lewis Burrows

Lewis Burrows

The Recanati/Miller Transplantation Institute and

Search for more papers by this author
Jonathan S. Bromberg

Jonathan S. Bromberg

The Recanati/Miller Transplantation Institute and

Search for more papers by this author
First published: 21 October 2002
Citations: 14
Sander S. Florman, MD,
Mount Sinai Hospital, Box 1104, One Gustave L. Levy Place, New York, NY 10029, USA.
Tel.: +1-212-241-8035
Fax: +1-212-996-9688
E-mail: [email protected]

Abstract

Abstract: Recurrence of hemolytic uremic syndrome (HUS) after kidney transplantation is frequent, occurring almost exclusively in patients with atypical HUS, which is not caused by Escherichia coli gastroenteritis and in which diarrhea is absent. Calcineurin inhibitors are associated with recurrence of HUS. In two children who underwent living donor kidney transplantation for atypical HUS, we pre-emptively employed sirolimus in a calcineurin inhibitor-free immunosuppression regimen. Both children had excellent early graft function, yet both developed severe recurrent disease and subsequently lost their grafts. Avoidance of calcineurin inhibitors did not prevent recurrence of severe HUS and graft loss. Transplantation for severe atypical HUS remains problematic.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.